We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.

August 13, 2021

August HealthXL Meeting Snapshot

Events
HealthXL team & HealthXL community
&

August HealthXL Meeting Snapshot 

Our meetings create a space for industry experts to connect and discuss the most current and evolving topics in the digital health space. This segment highlights key learnings and ideas cultivated by our network of payers, providers, pharmaceutical companies, health care and technology organizations. 

DTx Employer Partnerships - August 5th, 2021 

We have seen a significant number of employers starting to incorporate DTx products into their benefits plans (e.g. Pear Therapeutics reSET, Freespira, etc). Employers are an attractive market entry route as they tend to demand lower evidence thresholds than others, favoring case studies over RCTs. This is a strong market entry route in the US, particularly in the advent of brokering agencies helping employers select specific, best-in-class solutions for their employee base. 

However, this route is not without challenges. In the EU this market entry route is next to non-existent as companies focus much more strongly on regulatory frameworks such as NICE and DiGA. We have also seen DTx predominantly addressing tier one therapeutic areas being selected by employers. These include diabetes, weight control and behavioral health solutions. This market entry route is more difficult for those addressing other areas such as respiratory disease. Additionally, employers are generally extremely risk averse and can be slow to get on board with new technologies or systems. Pricing models are also still in development for employers choosing to offer DTx as a benefit. What we’re seeing is a rise in consolidation, with major players such as Teledoc acquiring smaller DTx companies and then going on to offer their services to employers in the form of bundles.

DTx Overview of Market and Deals - July 21st, 2021 

The DTx market is estimated to be worth between 7 and 9 billion US dollars in the next 5 to 7 years and Prescription Digital Therapeutics (PDT) are expected to be the future of the DTx industry, representing 57% of total DTx investment in 2020. Just over the past few months we have seen a lot of exits in the form of IPOs and SPACs. For DTx companies that become too big to get acquired (e.g. platform-based companies), IPOs are a great exit strategy. SPACS have become the trend lately, however, this exit strategy can be challenging for companies that aren’t yet ready to become public and may ultimately lead to some failures in the next few months/years. 

Of the companies they invest in, trait investors expect scalability, potential expansion to other therapeutic areas, clinical evidence and scientific foundation, prescribable and reimbursed solutions and user engagement. For some investors it is also important that companies have had real partnerships with relevant impact. 

Pharma-DTx partnerships are also still a work in progress with strategic alignment between the two parties being critical to success. As many of these partnerships are still in the early stages, ROI is hard to define and is not expected in the near future for pharma. The ROI also varies across departments as the KPIs are different depending on the department that leads the partnership (e.g. marketing, business development, R&D, etc). We may likely see pharma move from the partnerships model to the acquisition model in the next few years. This is not an entirely new model; traditionally, biotech companies have taken this path as they don’t have the capacity to commercialize themselves. However, there are still some doubts about pharma being the right stakeholder to acquire DTx companies. 

The volume of competitor solutions may be a blocker to patient and physician adoption. To combat this we will likely see the DTx industry evolve to a branded unique platform model that provides multiple digital health solutions.

Best Routes to Market for DTx in the US - July 20th, 2021 

What are the most scalable and sustainable routes to market for DTx companies in the US? Beyond clinical evidence, the right commercialization model is key to drive adoption of DTx. A number of DTx companies have chosen pharma partnerships as their route to market, but is pharma the safest and most efficient commercialization model for DTx companies? Employer and payer partnerships have proven to be great options in the US and D2C can also be a valuable approach, especially for new players that aim to gain traction faster and easily collect RWD to improve the product.  An unexplored potential path is via medtech companies that are also seeking new ways to reach their customers. Perhaps routes to market undergo iterations as the product gains traction.

Several factors were identified as key considerations for approaching Payors with digital health solutions:

1) Demonstration of economic savings 

2) Therapeutic area 

3) Demonstration of scalability 

4) Treatment duration period with a preference for finite interventions

There is a diversity of health plans in the US and the truism is that when you know one plan, you know one plan. IDNs are likely to be more receptive to digital health solutions as they are economically aligned to manage the total cost of care for patients. Larger, national health plans are also keen to support innovation and can be a good target. Regional plans are likely to be followers of national plans as opposed to taking the lead on innovation in this area. 

Self-insured employers have been a successful route to market for digital health businesses, especially where therapeutic area interests align and there is sufficient data to support efficacy. As this segment of the market evolves, the role of platforms such as Solera Health and Virgin Pulse should be noted as they can be gatekeepers for access to employers who want to move from point solutions to platform solutions for their employees where data/efficacy between applications can be monitored.

Bear in mind that Payors seek to manage their costs and historically this has meant designing policies with restrictions rather than incentives to access therapies. This mindset can inform how they design the promotion of DTx programs in the future. While you may consider reduced pricing for early adopters, be aware that reference pricing is out there already and depending on the maturity of the app, further price rises may be difficult to execute. Starting with an “at risk” pricing model to prove efficacy can be a successful way to gain traction and allow for better pricing negotiations at a later stage.

Want to join the conversation? Check out our website for upcoming meetings and event

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

Ready to read more? HealthXL members can access the full peak of the report on the HealthXL Community Hub.

Not yet a member of HealthXL? Download your 11 page snapshot of the report.

Download your 11 page snapshot

Connect with peers and share insights

Don't miss out on the discussion of the latest insights and reports on digital health. Meet with peers and take a deep dive for 75 minutes. Unlike at webinars, you can freely exchange experiences and insights to solve challenges and design the future of DTx.

Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Sustainable Business Models for DTx

16th August @ 10:45AM EDT

It is one of the key questions that every digital therapeutic (DTx) company must answer - what business model will set them up for success in the long run? Join this meeting to discuss this further and share your experiences with your peers working in this space.

Featuring
Elena Mustatea
Elena Mustatea
CEO, Bold Health
Rick Bartels
Rick Bartels
Managing Partner , DTxCC
Featuring
Elena Mustatea
Elena Mustatea
CEO, Bold Health
Rick Bartels
Rick Bartels
Managing Partner , DTxCC
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Payers Partnerships for DTx

17th August @ 10:45AM EDT

Digital Therapeutics (DTx) vendors face many challenges on their journey to commercialization, such as generating clinical data, health economics evidence and achieving regulatory status. Join this meeting to discuss this topic further and share your experiences with others working in this space.

Featuring
Elena Mustatea
Elena Mustatea
CEO, Bold Health
Kevin Darcy
Kevin Darcy
Director, Link Strategy at Veeva Systems
Featuring
Elena Mustatea
Elena Mustatea
CEO, Bold Health
Kevin Darcy
Kevin Darcy
Director, Link Strategy at Veeva Systems
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Sprint: How to Overcome the Blockers to DTx Adoption and Measure Success? (Part 2)

25th August @ 10:45AM EDT

While new legislations and rules (such as DiGA in Germany) have opened new options for reimbursement, adoption of digital therapeutics (DTx) remains insufficient to achieve the revenue expected from these solutions. Join this 2 part sprint to discuss this topic further.

Featuring
Mette Dyhrberg
Mette Dyhrberg
Founder & CEO, Mymee
Richard DeNunzio
Richard DeNunzio
SVP, Commercial at Click Therapeutics, Inc.
Featuring
Mette Dyhrberg
Mette Dyhrberg
Founder & CEO, Mymee
Richard DeNunzio
Richard DeNunzio
SVP, Commercial at Click Therapeutics, Inc.
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Masterclass: DTx Reimbursement in the US: Government-sponsored plans (Medicaid and Medicare)

30th August @ 10:45AM EDT

Are you a digital therapeutics (DTx) company seeking reimbursement in the US market? Join this masterclass led by the biopharma and DTx reimbursement expert Mike Pace to dive deeper into this topic.

Featuring
Michael Pace
Michael Pace
CEO & Founder at PalmHealth.co
Featuring
Michael Pace
Michael Pace
CEO & Founder at PalmHealth.co

Are you a HealthXL Member? See the Full Report Here

Non-HealthXL Member? You can purchase the report HERE

HealthXL Digital Health Meetings

Want to join the discussion now?

Join our Digital Health Meetings and take a deep dive for 75 minutes into topics like digital therapeutics, patient support, telehealth, clinical trials, dermatology and many more. These Meetings are not regular webinars: No audience, no recording and no hiding behind a screen. You actively participate in a discussion to solve your present challenges and design the future of digital health. And with a free account on our Community Hub, you stay connected and up-to-date on the latest news and insights, allowing you to fully immerse yourself in the topic before, during and after.

Executive 1-2-1 with the HealthXL Digital Health Community

15th August @11AM EDT

Do you want to network with other innovators and leaders in digital health? Are you looking to identify potential partners? Join us for the new HealthXL style of virtual speed networking and meet other members working in this space!

Featuring
Aahuti Rai
Aahuti Rai
Strategic Advisor, Healthcare Innovation at Four Points Consulting Ltd
Chris Wasden
Chris Wasden
Head of Pharma Speciality Solutions & Corporate Strategy, Twill
Featuring
Aahuti Rai
Aahuti Rai
Strategic Advisor, Healthcare Innovation at Four Points Consulting Ltd
Chris Wasden
Chris Wasden
Head of Pharma Speciality Solutions & Corporate Strategy, Twill
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Sustainable Business Models for DTx

16th August @ 10:45AM EDT

It is one of the key questions that every digital therapeutic (DTx) company must answer - what business model will set them up for success in the long run? Join this meeting to discuss this further and share your experiences with your peers working in this space.

Featuring
Elena Mustatea
Elena Mustatea
CEO, Bold Health
Rick Bartels
Rick Bartels
Managing Partner , DTxCC
Featuring
Elena Mustatea
Elena Mustatea
CEO, Bold Health
Rick Bartels
Rick Bartels
Managing Partner , DTxCC
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Payers Partnerships for DTx

17th August @ 10:45AM EDT

Digital Therapeutics (DTx) vendors face many challenges on their journey to commercialization, such as generating clinical data, health economics evidence and achieving regulatory status. Join this meeting to discuss this topic further and share your experiences with others working in this space.

Featuring
Elena Mustatea
Elena Mustatea
CEO, Bold Health
Kevin Darcy
Kevin Darcy
Director, Link Strategy at Veeva Systems
Featuring
Elena Mustatea
Elena Mustatea
CEO, Bold Health
Kevin Darcy
Kevin Darcy
Director, Link Strategy at Veeva Systems
Digital Health in Oncology
Digital Health in Oncology
Digital Health in Oncology
Digital Health in Oncology

Incentive Models for HCP & Care Team to Adopt Digital Health in Oncology

23rd August @ 10:45AM EDT

What are the best incentive models to encourage health care professionals (HCPs) and care teams to adopt digital health in oncology? Join this meeting to discuss this topic further with others working in this space.

Featuring
Susan Bratton
Susan Bratton
CEO & Founder at Savor Health
Ary Deleray
Ary Deleray
Personalized & Digital Health Strategy at Roche
Featuring
Susan Bratton
Susan Bratton
CEO & Founder at Savor Health
Ary Deleray
Ary Deleray
Personalized & Digital Health Strategy at Roche

What’s a Rich Text element?

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

Static and dynamic content editing

A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!

How to customize formatting for each rich text

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.